Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The restructuring also includes several executive departures.

Momenta President and CEO Craig Wheeler said on a Oct. 1 conference call the company conducted a

Read the full 577 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE